Home » News » VASGEN Wins Therapy Accelerator Funding

VASGEN Wins Therapy Accelerator Funding

London UK, 19th  August 2022: Vasgen Limited (“Vasgen” or “the Company”), a speciality biotech company, reports successfully competing in the Hertfordshire Science Partnership Therapy Accelerator competition administered by the University of Hertfordshire. Vasgen in collaboration with the University of Hertfordshire will initiate studies to develop a novel therapy to treat unmet needs in cardiovascular medicine.

Dr Salman Rahman, CEO and co-founder of Vasgen said:Cardiovascular disease remains the largest global healthcare challenge and is responsible for 32% of all deaths despite substantive progress in the management of coronary artery disease and stroke over recent decades. Funding from the Hertfordshire Science Partnership supporting our collaboration with the University of Hertfordshire will facilitate a new drug discovery programme applying our breakthrough AbIMP® platform to validate a promising cardiovascular target that could address significant unmet needs in cardiovascular medicine.”

Dr Helen Podmore, Senior Business Development Manager said: “The Therapy Accelerator programme was established to catalyse therapeutic innovation so we are very pleased to support this exciting new collaborative project between Vasgen and the University of Hertfordshire, which could lead to a breakthrough treatment for cardiovascular disease.”

-Ends-

Notes to Editors:

VASGEN LTD

Vasgen Limited is a London-based biotech company developing innovative ocular and cancer therapeutics to deliver precision medicines to patients.

The Company’s technologies include AbIMP® (an acronym for Antibody Inhibitor of Metalloprotease) a breakthrough antibody-based discovery platform allowing identification of highly selective inhibitors of metzincin metalloproteinases with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic antibody targeting ADAM15 for wet age-related macular degeneration. More information is available at www.vasgen.co.uk

For further information please contact:

Tel : +44 (0)207 691 2149

info@vasgen.co.uk

About Hertfordshire Science Partnership

The Hertfordshire Science Partnership is an innovative collaboration between the University of Hertfordshire and Hertfordshire LEP, which leverages the university’s state-of-the-art science facilities and academic expertise to boost the dynamic pharmaceutical, life sciences and agri-technology sectors in the East of England.